Clinical trials: Colorectal Cancer Recurrent
Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.
- Conditions
- Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
- Trial name
- NCT07140679
- Testing
- Biopsy Procedure, Biospecimen Collection, Colonoscopy
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Colorectal Cancer, Nausea and Vomiting
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy.
- Trial name
- NCT00381862
- Testing
- aprepitant, dexamethasone, fluorouracil
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Colorectal Carcinoma
Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma
feasibility of physical activity increase of physical conversation Quality of Life (optional) vascular and metabolic effects
- Trial name
- NCT01210313
- Testing
- Physical exercise
- Where
- 7 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Colorectal Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006046
- Testing
- monoclonal antibody hu3S193
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ludwig Institute for Cancer Research
Colorectal Cancer
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
RATIONALE: Brivanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00640471
- Testing
- cetuximab, brivanib alaninate
- Where
- 37 sites in Canada
- Volunteers
- 750 people
- Sponsor
- NCIC Clinical Trials Group
Gastric Polyps, Intestinal Polyps
Recurrence After Gastric and Intestinal Polyp Resection
This is a retrospective and prospective cohort study designed to evaluate the recurrence rate and identify risk factors after endoscopic resection of gastric and intestinal polyps.
- Conditions
- Gastric Polyps, Intestinal Polyps, Colon Polyps, Colorectal Polyps
- Trial name
- RAGIP (NCT07314554)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- LanZhou University
Colorectal Cancer
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004042
- Testing
- monoclonal antibody F19, iodine I 131 monoclonal antibody F19
- Where
- 3 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if the effectiveness of irinotecan combined with fluorouracil in treating colorectal…
- Trial name
- NCT00006103
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Volunteers
- 400 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Anal Cancer, Recurrent Anal Cancer
Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)
This protocol aims to determine toxicity and efficacy of re-irradiation for patients with recurrences from anal cancers with dose-escalated pencil beam proton therapy either pre-operative for marginally resectable recurrences or…
- Trial name
- ReRad III (NCT05055635)
- Testing
- Pencil beam proton therapy
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- University of Aarhus
Colorectal Cancer, Colorectal Cancer Recurrent
Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer
Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Although adjuvant chemotherapy improves survival after curative resection, its efficacy varies widely among patients.
- Conditions
- Colorectal Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Trial name
- SPLICE (NCT07226115)
- Testing
- SPLICE
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- City of Hope Medical Center
Rectal Cancer, Organ-Space Surgical Site Infection
Organ/Space Surgical Site Infection and Recurrence and Survival in Rectal Cancer Surgery
In rectal cancer surgery, the organ/space surgical site infection (O/S-SSI) has an impact on patient's prognosis. Its influence in the oncologic outcomes remains controversial.
- Trial name
- VINCat_PDO_2 (NCT06382415)
- Where
- Spain
- Volunteers
- 3,826 people
- Sponsor
- Hospital de Granollers
Colorectal Cancer, Diarrhea
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084721
- Testing
- celecoxib, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy…
- Trial name
- APOLLON (NCT02613221)
- Testing
- Panitumumab + TAS-102
- Where
- 32 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Colorectal Cancer
Early Diagnosis and Recurrence Monitoring of Colorectal Cancer
Colorectal cancer (CRC) has an insidious onset and its survival rate is closely related to clinical stage. While the 5-year survival rate of stage I patients exceeds 90%, it drops to 14% in stage IV.
- Trial name
- NCT06991452
- Testing
- Liquid biopsy
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Colorectal Cancer
Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, capecitabine, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00496704
- Testing
- capecitabine, gemcitabine hydrochloride, oxaliplatin
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Yonsei University
Tumors
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
- Trial name
- NCT00248404
- Testing
- NB1011
- Where
- 3 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Kiadis Pharma
Colorectal Cancer
Plasma Multi - Omics Detection for Evaluating Efficacy and Recurrence Risk in Oligometastatic Colorectal Cancer Conversion Therapy
This prospective study (PMEIRR-OCCCT) evaluates the utility of plasma multi-omics-including circulating tumor DNA (ctDNA), cell-free RNA (cfRNA), proteomics, and metabolomics-in assessing response to conversion therapy and…
- Trial name
- PMEIRR - OCCCT (NCT07492238)
- Testing
- Plasma Multi - omics Detection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiujuan Qu
Recurrent Breast Cancer, Recurrent Colon Cancer
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
This pilot clinical trial studies comprehensive gene sequencing in guiding treatment recommendations in patients with metastatic or recurrent solid tumors.
- Conditions
- Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer
- Trial name
- NCT01987726
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Colorectal Cancer
DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00550563
- Testing
- cholecalciferol, polymerase chain reaction, polymorphism analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer, Colorectal Cancer Metastatic
A Study of Famitinib in Patients With Advanced Colorectal Cancer
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the toxicity is manageable.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
- Trial name
- NCT01762293
- Testing
- Famitinib
- Where
- 2 sites in China
- Volunteers
- 154 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.